Logo image of THRD

Third Harmonic Bio Inc (THRD) Stock Fundamental Analysis

USA - NASDAQ:THRD - US88427A1079 - Common Stock

5.38 USD
0 (-0.09%)
Last: 7/30/2025, 8:00:01 PM
5.38 USD
0 (0%)
After Hours: 7/30/2025, 8:00:01 PM
Fundamental Rating

3

Overall THRD gets a fundamental rating of 3 out of 10. We evaluated THRD against 195 industry peers in the Pharmaceuticals industry. While THRD has a great health rating, there are worries on its profitability. THRD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year THRD has reported negative net income.
THRD had a negative operating cash flow in the past year.
THRD had negative earnings in each of the past 5 years.
THRD had a negative operating cash flow in each of the past 5 years.
THRD Yearly Net Income VS EBIT VS OCF VS FCFTHRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.10%, THRD is in the better half of the industry, outperforming 61.34% of the companies in the same industry.
With a decent Return On Equity value of -19.60%, THRD is doing good in the industry, outperforming 70.62% of the companies in the same industry.
Industry RankSector Rank
ROA -19.1%
ROE -19.6%
ROIC N/A
ROA(3y)-12.77%
ROA(5y)-42.74%
ROE(3y)-13.19%
ROE(5y)-866.71%
ROIC(3y)N/A
ROIC(5y)N/A
THRD Yearly ROA, ROE, ROICTHRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

THRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THRD Yearly Profit, Operating, Gross MarginsTHRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

THRD has more shares outstanding than it did 1 year ago.
There is no outstanding debt for THRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
THRD Yearly Shares OutstandingTHRD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
THRD Yearly Total Debt VS Total AssetsTHRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

THRD has an Altman-Z score of 19.69. This indicates that THRD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of THRD (19.69) is better than 93.30% of its industry peers.
THRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.69
ROIC/WACCN/A
WACCN/A
THRD Yearly LT Debt VS Equity VS FCFTHRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 54.10 indicates that THRD has no problem at all paying its short term obligations.
THRD's Current ratio of 54.10 is amongst the best of the industry. THRD outperforms 100.00% of its industry peers.
THRD has a Quick Ratio of 54.10. This indicates that THRD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 54.10, THRD belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 54.1
Quick Ratio 54.1
THRD Yearly Current Assets VS Current LiabilitesTHRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

THRD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -89.33%.
EPS 1Y (TTM)-89.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, THRD will show a small growth in Earnings Per Share. The EPS will grow by 1.93% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.11%
EPS Next 2Y11.22%
EPS Next 3Y7.35%
EPS Next 5Y1.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THRD Yearly Revenue VS EstimatesTHRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 2M 4M 6M 8M 10M
THRD Yearly EPS VS EstimatesTHRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

THRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THRD Price Earnings VS Forward Price EarningsTHRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THRD Per share dataTHRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.22%
EPS Next 3Y7.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THRD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Third Harmonic Bio Inc

NASDAQ:THRD (7/30/2025, 8:00:01 PM)

After market: 5.38 0 (0%)

5.38

0 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06
Earnings (Next)11-05 2025-11-05
Inst Owners67.3%
Inst Owner Change0%
Ins Owners0.48%
Ins Owner Change-66.04%
Market Cap242.80M
Analysts43.33
Price Target3.06 (-43.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.69%
Min EPS beat(2)-38.41%
Max EPS beat(2)-16.98%
EPS beat(4)1
Avg EPS beat(4)-14.5%
Min EPS beat(4)-38.41%
Max EPS beat(4)5.59%
EPS beat(8)5
Avg EPS beat(8)11.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.41%
PT rev (3m)-34.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.07%
EPS NY rev (1m)0%
EPS NY rev (3m)7.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS6.04
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.1%
ROE -19.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.77%
ROA(5y)-42.74%
ROE(3y)-13.19%
ROE(5y)-866.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 54.1
Quick Ratio 54.1
Altman-Z 19.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-89.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y26.11%
EPS Next 2Y11.22%
EPS Next 3Y7.35%
EPS Next 5Y1.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.31%
EBIT Next 3Y-16.07%
EBIT Next 5Y-2.76%
FCF growth 1Y-24.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.48%
OCF growth 3YN/A
OCF growth 5YN/A